趋化因子 CCL27 是一种新型血浆生物标志物，可用于鉴定 EBV 衣壳抗原特异性 IgA 血清阳性人群中的鼻咽癌患者。
Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
机构信息
Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Department of Laboratory Medicine, Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou, 450100, China.
出版信息
BMC Cancer. 2018 Jan 2;18(1):9. doi: 10.1186/s12885-017-3718-2.
BACKGROUND
To investigate the predictive value of chemokine CCL27 for identifying early stage nasopharyngeal carcinoma (NPC) patients within a population seropositive for Epstein-Barr virus (EBV) capsid antigen-specific IgA (VCA-IgA).
METHODS
CCL27 in plasma samples from 104 NPC patients, 112 VCA-IgA-positive healthy donors, and 140 VCA-IgA-negative normal subjects was measured by ELISA. Expression of CCL27 in nasopharyngeal tissue from 20 VCA-IgA-positive healthy donors and 20 NPC patients was examined by immunohistochemical staining.
RESULTS
Levels of CCL27 in the plasma of VCA-IgA-positive healthy donors (607.33 ± 218.81 pg/ml) were significantly higher than the levels in all NPC patients (437.09 ± 217.74, P = < 0.0001) and in the subset of patients with early stage NPC (463.85 ± 226.17, P = 0.0126). Plasma CCL27 levels were significantly lower in the VCA-IgA-negative normal subjects (358.22 ± 133.15 pg/ml) than in either the VCA-IgA-positive healthy donors (P < 0.0001) or the NPC patients (P = 0.0113). CCL27 protein was detected in 16 of 20 (80%) nasopharyngeal tissue samples from VCA-IgA-positive healthy donors and in 3 of 20 (15%) tumor tissue samples from NPC patients. There was no relationship between CCL27 levels and VCA-IgA titers or plasma EBV DNA content. Receiver operating characteristic (ROC) curves demonstrated that plasma CCL27 levels had a sensitivity of 67.00%, a specificity of 73.10%, and an area under the ROC of 0.725 (95% confidence interval [CI]: 0.657-0.793) for distinguishing between NPC patients and VCA-IgA-positive healthy donors. Further analysis showed that CCL27 levels could distinguish between early stage NPC patients and VCA-IgA-positive healthy donors with an area under the ROC of 0.712 (95% CI: 0.560-0.865), a sensitivity of 59.80%, and a specificity of 84.60%.
CONCLUSIONS
Chemokine CCL27 could successfully identify NPC patients within a VCA-IgA-positive population.
背景
为了探究趋化因子 CCL27 在识别 EBV 衣壳抗原特异性 IgA（VCA-IgA）阳性人群中的早期鼻咽癌（NPC）患者方面的预测价值。
方法
采用 ELISA 法检测 104 例 NPC 患者、112 例 VCA-IgA 阳性健康供者和 140 例 VCA-IgA 阴性正常对照者的血浆 CCL27 水平。采用免疫组化染色法检测 20 例 VCA-IgA 阳性健康供者和 20 例 NPC 患者鼻咽组织中 CCL27 的表达。
结果
VCA-IgA 阳性健康供者的血浆 CCL27 水平（607.33±218.81pg/ml）显著高于所有 NPC 患者（437.09±217.74，P＜0.0001）和早期 NPC 患者（463.85±226.17，P=0.0126）。VCA-IgA 阴性正常对照者的血浆 CCL27 水平（358.22±133.15pg/ml）显著低于 VCA-IgA 阳性健康供者（P＜0.0001）和 NPC 患者（P=0.0113）。20 例 VCA-IgA 阳性健康供者中有 16 例（80%）的鼻咽组织中检测到 CCL27 蛋白，而 20 例 NPC 患者中有 3 例（15%）的肿瘤组织中检测到 CCL27 蛋白。CCL27 水平与 VCA-IgA 滴度或血浆 EBV DNA 含量均无相关性。受试者工作特征（ROC）曲线表明，血浆 CCL27 水平对 NPC 患者与 VCA-IgA 阳性健康供者的鉴别具有 67.00%的灵敏度、73.10%的特异性和 0.725 的 ROC 曲线下面积（95%CI：0.657-0.793）。进一步分析显示，CCL27 水平对早期 NPC 患者与 VCA-IgA 阳性健康供者的鉴别具有 0.712 的 ROC 曲线下面积（95%CI：0.560-0.865）、59.80%的灵敏度和 84.60%的特异性。
结论
趋化因子 CCL27 可成功识别 VCA-IgA 阳性人群中的 NPC 患者。
Zotero 插件